Back to Search Start Over

Effect of food on the pharmacokinetic characteristics of a single oral dose of LCB01-0371, a novel oxazolidinone antibiotic.

Authors :
Sunwoo J
Kim YK
Choi Y
Yu KS
Nam H
Cho YL
Yoon S
Chung JY
Source :
Drug design, development and therapy [Drug Des Devel Ther] 2018 Jun 11; Vol. 12, pp. 1707-1714. Date of Electronic Publication: 2018 Jun 11 (Print Publication: 2018).
Publication Year :
2018

Abstract

Background: LCB01-0371 is a novel oxazolidinone antibiotic that blocks protein production by binding to bacterial 23S ribosomes. This antibiotic is active against Gram-positive bacteria. This study aimed to evaluate the effect of food on the pharmacokinetics (PKs) of LCB01-0371 and evaluate its safety profile.<br />Subjects and Methods: A randomized, open-label, two-way crossover study was performed in 18 healthy Korean male subjects. All subjects received a single oral 800 mg dose of LCB01-0371 in each period under fed or fasting condition with a 7-day washout in between. The fed condition was defined as consumption of a meal of 800-1,000 kcal containinį50% of fat content. Serial blood samples were collected over 24 h after dosing, and the PK parameters were calculated by noncompartment analysis. All available data of the subjects who received LCB01-0371 at least once were included in the safety data summaries.<br />Results: In the fed condition, both the maximum plasma concentration ( C <subscript>max</subscript> ) and the total systemic exposure (area under the plasma concentration-time curve from time zero to the last observed time point [AUC <subscript>last</subscript> ]) decreased by ~33% and 10%, respectively. The time to reach C <subscript>max</subscript> was delayed by ~1.25 h in the fed condition, whereas the mean elimination half-life remained similar in both conditions. In the fed/fasting condition, the geometric mean ratios and 90% CI of the C <subscript>max</subscript> and AUC <subscript>last</subscript> were 0.666 (0.470-0.945) and 0.897 (0.761-1.057), respectively. There were no drug-related adverse events (AEs) or serious AEs.<br />Conclusion: Although the T <subscript>max</subscript> after a single oral 800 mg dose of LCB01-0371 was slightly delayed under the fed condition compared to the fasting condition, the total systemic exposure was similar under both conditions. Therefore, LCB01-0371 could be administered regardless of food intake.<br />Competing Interests: Disclosure Heesook Nam and Young Lag Cho are LegoChem Biosciences, Inc. employees. The other authors report no conflicts of interest in this work.

Details

Language :
English
ISSN :
1177-8881
Volume :
12
Database :
MEDLINE
Journal :
Drug design, development and therapy
Publication Type :
Academic Journal
Accession number :
29928114
Full Text :
https://doi.org/10.2147/DDDT.S155657